+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Epigenetics in Psychiatry

  • ID: 2857103
  • Book
  • October 2018
  • 664 Pages
  • Elsevier Science and Technology
1 of 3

Epigenetics in Psychiatry covers all major areas of psychiatry in which extensive epigenetic research has been performed, fully encompassing a diverse and maturing field, including drug addiction, bipolar disorder, epidemiology, cognitive disorders, and the uses of putative epigenetic-based psychotropic drugs. Uniquely, each chapter correlates epigenetics with relevant advances across genomics, transcriptomics, and proteomics. The book acts as a catalyst for further research in this potentially very important and useful area of psychiatry.

The elucidation of basic principles of epigenetic biology points to the creation of more optimal and effective therapies for major classes of psychiatric disease. In this regard, epigenetic therapy, the use of drugs to correct epigenetic defects, may help in the pharmacotherapy of patients with these disorders. With time, such advances may eventually point to replacements for psychotropic drugs presently of symptomatic value and low efficacy. Moreover, there is evidence to suggest that other forms of treatment commonly used in the management of psychiatric disorders, like psychotherapy and electroconvulsive therapy, may also act by epigenetic mechanisms.

  • Chapters review fascinating new areas of research across neuronal stem cells, cognitive disorders, and transgenerational epigenetics through drug addiction
  • Relates broad advances in psychiatric epigenetics to a modern understanding of the genome, transcriptome, and protein
  • Catalyzes knowledge discovery in both basic epigenetic biology and clinical application as epigenetic targets for drug discovery
Note: Product cover images may vary from those shown
2 of 3

1. Introduction 2. Outline of Epigenetics 3. History of Epigenetics in Psychiatry 4. Role of Epigenetics in the Neural Stem Cell and Neuron 5. Role of Epigenetics in the Brain 6. Epigenetic Epidemiology of Psychiatric Disorders 7. Laboratory Techniques in Psychiatric Epigenetics 8. Laboratory Models in Psychiatric Epigenetics 9. DNA Methylation and Histone Changes in Schizophrenia 10. Non-Coding RNAs and Major Psychosis 11. Epigenetics and Bipolar Disorder 12. Epigenetics and Major Depressive Disorder 13. Epigenetics and Suicide 14. Epigenetics of Anxiety Disorder and Post-Traumatic Stress Disorder 15. Epigenetics and Cognitive Disorders 16. Epigenetics and Mental Retardation 17. Epigenetics of Pervasive Developmental Disorders and ADHD 18. Epigenetics and Drug Addiction 19. Epigenetic Effects of Currently-Used Psychotropic Drugs 20. Drugs Affecting DNA Methylation in Psychiatric Disorders 21. Histone Deacetylase Inhibitors and Psychiatric Disorders 22. The Social Environment and Epigenetics in Psychiatry 23. Nutritional Influences on Epigenetics in Psychiatry 24. Transgenerational Epigenetics and Psychiatric Disorders

Note: Product cover images may vary from those shown
3 of 3
Peedicayil, Jacob
Dr. Jacob Peedicayil is a Professor in the Department of Pharmacology and Clinical Pharmacology, at the Christian Medical College in Vellore, India. He has published 46 review papers, 3 book chapters and is engaged in various editorial review boards and journal positions. His interests include theoretical research in psychiatric epigenetics and muscle-based pharmacology.
Grayson, Dennis R.
Dr. Grayson has been interested in mechanisms associated with gene expression for over 20 years. He joined the laboratory of Dr. James E. Darnell, Jr. at the Rockefeller University on 1984 to study cell-type specific transcription factors. This led to the identification of HNF3A as a hepatocyte nuclear factor important for activating the expression of multiple genes in hepatocytes. In 1988, Dr. Grayson joined the Fidia-Georgetown Institute for the Neurosciences and with the support of Dr. Erminio Costa, initiated a program in studying gene expression in neurons. From 1994-1998, he moved to the Allegheny University of the Health Sciences in Pittsburgh and developed a program in molecular psychiatry. He continued his interests in psychiatry and joined the Psychiatric Institute in 1998. This represented a unique opportunity to join his long time collaborators, Drs. Costa and Guidotti to pursue molecular underpinnings of schizophrenia. Dr. Grayson has received NRSA post-doctoral support, R01 and K04 funding from the NIH over the years. He has published over 100 papers in peer-reviewed journals and actively reviews NIH grants and post-doctoral fellowships. In addition, Dr. Grayson has been invited to speak at numerous national and international meetings.
Avramopoulos, Dimitri
Dr. Dimitrios Avramopoulos is an Associate Professor of Psychiatry and Behavioral Sciences in the McKusick-Nathans Institute of Genetic Medicine. He holds a medical degree from the National and Kapodistrian University of Athens and a doctorate of philosophy in human genetics from the University of Crete School of Medicine. Dr. Avramopoulos completed a fellowship in psychiatry and pediatric genetics at the Johns Hopkins University School of Medicine before joining the Johns Hopkins faculty in 2002. Dr. Avramopoulos's research focuses on the complex genetics of disorders like schizophrenia and Alzheimer's disease. His interest is in understanding how genetic variants increase disease risk and identify the opportunities for intervention.
Note: Product cover images may vary from those shown